Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of human lung cancer cell A549 lines treated with the chemotherapeutic drug motexafin gaolinium at 4, 12 and 24h timepoints

ABSTRACT: Human lung cancer (A549) cells were treated 50uM of the metal cation-containing chemotherapeutic drug motexafin gadolinium (MGd) for 4, 12, and 24 hrs and expression compared to control cells (treated with 5% mannitol for the same length of time)

ORGANISM(S): Homo sapiens

SUBMITTER: Mazen Karaman

PROVIDER: E-GEOD-2189 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.

Magda Darren D Lecane Philip P Miller Richard A RA Lepp Cheryl C Miles Dale D Mesfin Mimi M Biaglow John E JE Ho Vincent V VV Chawannakul Danny D Nagpal Shailender S Karaman Mazen W MW Hacia Joseph G JG

Cancer research 20050501 9

To gain a better understanding of the mechanism of action of the metal cation-containing chemotherapeutic drug motexafin gadolinium (MGd), gene expression profiling analyses were conducted on plateau phase human lung cancer (A549) cell cultures treated with MGd. Drug treatment elicited a highly specific response that manifested in elevated levels of metallothionein isoform and zinc transporter 1 (ZnT1) transcripts. A549 cultures incubated with MGd in the presence of exogenous zinc acetate displa ...[more]

PMID: 15867382

Similar Datasets

A549 teatement with MGd

Project description:Human lung cancer (A549) cells were treated 50uM of the metal cation-containing chemotherapeutic drug motexafin gadolinium (MGd) for 4, 12, and 24 hrs and expression compared to control cells (treated with 5% mannitol for the same length of time) Keywords: dose response

2005-05-01 | GSE2189 | GEO

Transcription profiling of human lung cancer cell A549 lines treated with the chemotherapeutic drug motexafin gaolinium at 4, 12 and 24h timepoints

| S-ECPF-GEOD-2189 | biostudies-other

Transcription profiling of mouse primary macrophages treated with the chemotherapeutic agent, 5,6-dimethylxanthenone-4-acetic acid,

Project description:Vascular disrupting agents (VDA) represent a novel approach to the treatment of cancer, resulting in collapse of tumor vasculature and tumor death. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a VDA currently in advanced Phase II clinical trials, yet its precise mechanism of action is unknown despite extensive preclinical and clinical investigations. The data presented herein demonstrate that DMXAA is a novel and specific activator of the TBK1-IRF-3 signaling pathway. DMXAA treatment of primary murine macrophages resulted in robust IRF-3 activation, a ~750-fold increase in IFN-beta mRNA and, in contrast to the potent Toll-like receptor 4 (TLR4) agonist, lipopolysaccharide (LPS), signaling was independent of mitogen-activated protein kinase (MAPK) activation and elicited minimal NF-kappaB-dependent gene expression. DMXAA-induced signaling was critically dependent on the IRF-3 kinase, TBK1, and IRF-3, but MyD88-, TRIF-, IPS-1/MAVS-, and IKKbeta-independent, thus excluding all known TLRs and cytosolic helicase receptors. DMXAA pretreatment of murine macrophages induced a state of tolerance to LPS and vice versa. In contrast to LPS stimulation, DMXAA-induced IRF-3 dimerization and IFN-beta expression were inhibited by salicylic acid (SA). These findings detail a novel pathway for TBK-1-mediated IRF-3 activation and provide new insights into the mechanism of this new class of chemotherapeutic drugs. Experiment Overall Design: Microarray analysis was carried out using AffymetrixÂ® mouse array 430A_2 exposed to total RNA prepared from C57BL/6J or IFN-beta-/- macrophages that had been treated with medium alone or DMXAA for 3 h. Fold-induction was calculated using AffymetrixÂ® GeneChipÂ® Operating Software. A >3-fold increase or decrease between inducible and basal mRNA levels was set as the criteria for inclusion of a gene as modulated.

2008-06-15 | E-GEOD-7194 | biostudies-arrayexpress

Transcription profiling of barley anthers: effect of mannitol treatment on microspore embryogenesis

Project description:we analyzed the anther transcriptome before and after 4 days of mannitol treatment using the 22k Barley1 GeneChip Experiment Overall Design: one genotype (DH line 46), two treatments (4 days of mannitol treatment and control) and three repeats each treatment

2009-05-11 | E-GEOD-10330 | biostudies-arrayexpress

Modeling cellular pliancy-dependent oncogene-induced signaling and chemotherapeutic response during breast tumorigenesis

Project description:Modeling cellular pliancy-dependent oncogene-induced signaling and chemotherapeutic response during breast tumorigenesis

2021-06-30 | GSE153216 | GEO

Transcription profiling of A549 lung cancer cultures treated with the lead compound PCI-5002 supplemeted with zinc reveals synthesis and anticancer properties of water-soluble zinc ionophores

Project description:We have shown that water solubilized versions of a zinc ionophore increase intracellular concentrations of free zinc and have antiproliferative activity in exponential phase A549 lung cancer cultures. The gene expression profiles of A549 lung cancer cultures treated with the lead compound PCI-5002 reveal the activation of stress response pathways. Medium supplementation with zinc (25 Î¼M) led to activation of additional oxidative stress response as well as apoptotic pathways. We propose that the pharmacologic delivery of zinc to tumors using water solubilized ionophores is a potential approach to cancer therapy. Experiment Overall Design: A549 human lung cancer cells (1 x 105 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, sapphyrin PCI-5002 (10 Î¼M final concentration), ZnOAc2 (25 Î¼M final concentration), the combination, or control (5% mannitol) solution was added to the cultures. Each experiment was performed in triplicate. After incubation, all cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated and subjected to analysis on Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA), as described. ArrayAssist software (Stratagene/Affymetrix) and the RMA (Robust Microarray Analysis) algorithm were used to generate scaled gene expression values.

2008-06-15 | E-GEOD-6960 | biostudies-arrayexpress

Transcription profiling of human hepatocellular carcinoma cells Hep3B and HepG2 after treatment with the chemotherapeutic drug bleomycin

Project description:Hep3B cells were treated with the chemotherapeutic drug bleomycin. RNA was isolated after 18 h, 24 h and 36 h. The status of the gene expression was examined in response to treatment with bleomycin,

2009-09-01 | E-MEXP-1213 | biostudies-arrayexpress

Influence of substrate stiffness on chemotherapeutic response in breast cancer

Project description:Influence of substrate stiffness on chemotherapeutic response in breast cancer

| PRJNA418945 | ENA

Transcription profiling of rat hearts isolated perfused and exposed to doxorubicin

Project description:We used microarrays to detail transcriptional changes in the rat heart in response to doxorubicin, a chemotherapeutic drug known to induce cardiac disfunction/heart failure Experiment Overall Design: Langendorff perfusion of isolated hearts with/without doxorubicin

2009-01-14 | E-GEOD-12260 | biostudies-arrayexpress

Transcription profiling of rat cerebellar granular cells cultured in the presence of Shh for 24h and then pulsed with Bmp2 or vehicle for up to 24h

Project description:Proliferating cerebellar granular cells were cultured in presence of Shh for 24h (3ug/ml) and then pulsed for additional 24h with Bmp2 or vehicle. Cells then were lysed and mRNA extracted. Microarray data from cells treated with Bmp2 was referred to the control not treated with Bmp2.

2007-06-07 | E-MEXP-1129 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data